A new study in rats suggests that xylazine, the active ingredient in a non-opioid veterinary tranquilizer not approved for human use, can worsen the life-threatening effects of opioids. The findings imply that when used in combination with opioid drugs such as fentanyl and heroin, xylazine may damage the ability of the brain to get enough oxygen, which is one of the most dangerous effects of opioid drugs and can lead to death. The study, published in Psychopharmacology, was led by researchers at the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.
Research has shown xylazine is often added to illicit opioids, including fentanyl, and that xylazine has been increasingly detected in the illicit opioid supply. While some people knowingly use fentanyl and xylazine in combination, many people do not know if the drugs they plan to use contain fentanyl, xylazine, or both. This combination can be extremely dangerous, and in April 2023, the U.S. government declared fentanyl adulterated or associated with xylazine as an emerging drug threat.
"Drug mixtures containing both xylazine and opioids such as fentanyl demonstrate how rapidly the drug supply can change, and how dangerous products can proliferate despite rampant overdose deaths,” said Nora Volkow, M.D., director of NIDA. “Understanding the mechanisms behind how xylazine contributes to drug overdoses is essential to enable us to develop interventions that can reverse overdoses and save lives. In the meantime, naloxone, an opioid overdose reversal medication, should always be administered in the event of an overdose because xylazine is most often combined with opioids such as fentanyl.”
Xylazine is known to cause sedation and dangerously slow breathing, heart rate, and low blood pressure in people. The harms of xylazine and risk of fatal overdose are also known to increase when it is used in combination with other central nervous system depressants like alcohol, benzodiazepines, and opioids like fentanyl or heroin. However, the mechanisms underlying the effects of xylazine and its interaction with opioid drugs are largely unknown. In this study, a research team led by the NIDA Intramural Research Program conducted a series of experiments in rats to better understand the effects of xylazine as an adulterant to fentanyl and heroin.
For the first stage of the study, xylazine was administered on its own, and in different doses, to assess the effects of xylazine on movement, temperature, and oxygen levels in the brain. Even with low doses of xylazine, researchers observed known effects of the drug, including sedation, muscle relaxation, and decreased body temperature. Researchers also observed a modest decrease in brain oxygen levels, which was long-lasting, and dose-dependent, meaning the decrease in oxygen levels in the brain was stronger when more xylazine was administered.
In the second phase of the study, either fentanyl or heroin was administered to examine the changes in levels of oxygen in the brain after being exposed to these drugs. Researchers then compared the effects between the combination of either fentanyl and xylazine or heroin and xylazine. In contrast to the modest and prolonged decreases in brain oxygen levels observed with xylazine, administering fentanyl or heroin on their own generated an initial rapid and strong decrease in brain oxygen levels, resulting from slowed breathing. This was followed by a slower and more prolonged brain oxygen increase.
However, when the xylazine-fentanyl mixture or the xylazine-heroin mixture were administered, the rebounding increase in oxygen to the brain was eliminated, and the brain oxygen levels therefore remained lower for a longer period compared to fentanyl or heroin alone. In addition, the xylazine-heroin mixture resulted in a much stronger and more prolonged initial decrease in brain oxygen compared to heroin alone.
These findings suggest that the addition of xylazine to fentanyl or heroin disrupts the mechanism that the brain uses to counteract a rapid loss of oxygen after being exposed to opioid drugs. The authors therefore hypothesize that xylazine is contributing to overdose deaths involving opioids.
“The risks that people face from a drug contaminated with fentanyl are very concerning, and this study provides evidence to suggest that the addition of xylazine is exacerbating those risks,” said Eugene A. Kiyatkin, M.D., Ph.D., lead author on the paper and senior associate scientist in the NIDA Behavioral Neuroscience Branch. “Further research is needed to explore how these observations may apply in humans, and to continue to parse the complex role of illicit drug combinations with xylazine and risk of overdose.”
The United States has experienced a massive change in its illicit drug supply over the past several years, most notably through the rapid expansion of illicit fentanyl, a cheap, very potent synthetic opioid drug. There has been a corresponding dramatic increase in overdose deaths, which have now plateaued at more than 100,000 people dying in the U.S. annually.
This press release describes basic research findings. Basic research increases our understanding of human behavior and biology, which is foundational to advancing new and better ways to prevent, diagnose, and treat disease. Science is an unpredictable and incremental process— each research advance builds on past discoveries, often in unexpected ways. Most clinical advances would not be possible without the knowledge of fundamental basic research. To learn more about basic research, visit Basic Research – Digital Media Kit (NIH).
For more information on substance and mental health treatment programs in your area, call the free and confidential National Helpline 1-800-662-HELP (4357) or visit www.FindTreatment.gov.
Reference
S Choi, MR Irwin, & E Kiyatkin. Xylazine effects on opioid-induced brain hypoxia. Psychopharmacology. DOI: 10.1007/s00213-023-06390-y (2023).
###
About the National Institute on Drug Abuse (NIDA): NIDA is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. For more information about NIDA and its programs, visit www.nida.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
About substance use disorders: Substance use disorders are chronic, treatable conditions from which people can recover. In 2021, over 46 million people in the United States had at least one substance use disorder. Substance use disorders are defined in part by continued use of substances despite negative consequences. They are also relapsing conditions, in which periods of abstinence (not using substances) can be followed by a return to use. Stigma can make individuals with substance use disorders less likely to seek treatment. Using preferred language can help accurately report on substance use and addiction. View NIDA’s online guide.
NIH…Turning Discovery Into Health®
